Vold Steven D

Sheybani Arsham, Vera Vanessa, Grover Davinder S, Vold Steven D, Cotter Frank, Bedrood Sahar et al.

This study compared gel stents to trabeculectomy for open-angle glaucoma. Gel stents were noninferior for IOP reduction, with fewer interventions and faster visual recovery, but trabeculectomy achieved lower mean IOP.

Baker N Douglas, Barnebey Howard S, Moster Marlene R, Stiles Michael C, Vold Steven D, Khatana Anup K et al.

This study compared MicroShunt and trabeculectomy for glaucoma; trabeculectomy achieved better IOP reduction and success rates, making it more effective at one year.

Cui Qi N, Hays Ron D, Tarver Michelle E, Spaeth George L, Paz Sylvia H, Weidmer Beverly et al.

Researchers developed a new patient-reported survey (Glaucoma Outcomes Survey) to assess health-related quality of life in glaucoma patients considering MIGS. This tool will help understand MIGS's impact on patients' vision-targeted well-being.

Hoeh Helmut, Vold Steven D, Ahmed Iqbal K, Anton Alfonso, Rau Magda, Singh Kuldev et al.

This study found CyPass Micro-Stent implantation combined with cataract surgery for open-angle glaucoma safely reduced intraocular pressure and medication use. This offers a promising, low-complication treatment option.

Jea Seung Youn, Mosaed Sameh, Vold Steven D, Rhee Douglas J

This study found that a failed trabectome procedure does not negatively affect the success rate or complication profile of a subsequent trabeculectomy, suggesting it's a safe initial surgical option.

Rylander Nathan R, Vold Steven D

This study calculated yearly costs of glaucoma drops, finding generic timolol cheapest ($150.81) and some brand-name/multi-dose drugs most expensive (up to $873.98), highlighting cost's impact on treatment decisions.

Vold Steven D, Rylander Nathan

Healon5 effectively stopped an intraoperative expulsive hemorrhage in a high-risk patient, suggesting its potential as a tamponade agent to manage this severe surgical complication.

Vold Steven D, Riggs William L, Jackimiec John

This study found significant yearly cost differences among topical glaucoma medications, highlighting cost as a factor for clinicians and patients in treatment selection.